Vitrafy Life Sciences Ltd. · ASX:VFY
Vitrafy Life Sciences — H1 FY2025 Earnings Presentation
37 slides from Vitrafy Life Sciences's earnings presentation, Feb 6, 2025
Slide 1: Half-Year FY2025 Results Presentation
BUSINESS & FINANCIAL UPDATE Half-Year FY2025 Results Presentation PRESERVING LIFE Improving the quality of healthcare treatments by providing effective cryopreservation solutions February 2025
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer This presentation is provided by Vitrafy Life Sciences Limited (ACN 622 720 254) (“Vitrafy” or “the Company”). This expectations in relation to any such statements or any change in events, conditions or circumstances on which any Document is current as at the date of th
Slide 3: Key Executives
Key Executives KATE MUNNINGS BRENT OWENS ( Chief Executive Officer & SIMON MARTIN (Deputy Chief Executive Officer, (Chief Financial Officer) Managing Director) Co-Founder & Executive Director) Extensive experience across the 25 years’ experience in executive and Creative entrepreneur and co-inventor
Slide 4: Vitrafy addresses the vital global need for enhanced cryopreservation solutions
Vitrafy addresses the vital global need for enhanced cryopreservation solutions. Vitrafy’s vision is to improve the quality of healthcare treatments by providing effective cryopreservation technology, preserving life. 4
Slide 5: Vitrafy – A New Standard of Quality
Vitrafy – A New Standard of Quality Vitrafy’s cryopreservation technology integrates software and hardware solutions to deliver quality outcomes. Sample quality retention software platform Patient - Sample Sample Preparation Deep Freeze Application (e.g. Collection Storage & Logistics platelet trans
Slide 6: Vitrafy's IPO - November 26, 2024
Vitrafy’s IPO - November 26, 2024 In November 2024, Vitrafy successfully completed a $35.0m capital raise via an initial public offer (“IPO”) on the ASX to fund the next phase of growth of the Company. • The Vitrafy IPO was strongly supported by its long-term investor base, resulting in demand for t
Slide 7: Highlights since IPO
Highlights since IPO Our mission is to become the global leader in cryopreservation and set new industry quality standards for cryopreserved materials, preserving life. USA Business growth Leveraging Strong Scientific Data Product Development Delivery Commenced USA recruitment with Continued positiv
Slide 8: Market Development & Commercialisation
1 Market Development & Commercialisation 8
Slide 9: Executive Summary
Executive Summary Vitrafy has continued to achieve positive results from scientific and validation studies, further strengthening our market position across priority application areas. During January 2025, outbound business development activities commenced in the USA, expanding the company’s commerc
Slide 10: Animal Reproduction – Salmon
Animal Reproduction – Salmon Vitrafy strengthens its long-term commercial relationship with Huon Aquaculture by continuing to improve post thaw fertilisation rates of cryopreserved salmon milt. Progress Update 80% • Vitrafy and Huon Aquaculture entered into a 70% 68% 65% 3-year contract; 60% • Vitra
Slide 11: Animal Reproduction – Bovine
Animal Reproduction – Bovine Vitrafy has continued to optimise the protocols of cryopreserving Bull semen, which has resulted in further post thaw motility when compared to previously released results. Progress Update 100% • Following the success of the Phase 1 study with Select 90% Sires Inc (SSI),
Slide 12: Blood Platelets
Blood Platelets Vitrafy has successfully passed security clearance and commenced the Phase 1 study with USAISR to validate the post thaw recovery of blood platelets. Progress Update • In February 2025, Vitrafy commenced the Phase 1 study of Blood Platelets under the Cooperative Research and Developm
Slide 13: Cell & Gene Therapy
Cell & Gene Therapy Growing commercial interest and market awareness from within the Cell & Gene Therapy (“CGT”) industry underpinned by robust and expanding scientific validation Progress Update • The emerging industry of Cell and Gene Therapy remains a priority application area for Vitrafy. As the
Slide 14: Product & Technology Development
2 Product & Technology Development 14
Slide 15: Product Development
Product Development Vitrafy continues to invest in the next generation of Cryopreservation Technology to ensure the Company is able to effectively scale with anticipated demand. Our technology advancements are determined by the market and end user requirements, guided by our collaboration partner fe
Slide 16: Vitrafy's Cryopreservation Hardware (VCU2)
Vitrafy’s Cryopreservation Hardware (VCU2) Vitrafy has partnered with health-tech innovation and manufacturing company, Planet Innovation, to support the development of VCU2.0 and preparation for its outsourced manufacturing, principally in the US. Progress Update • During January 2025, Phase 1 of 3
Slide 17: VCU1 > VCU2
VCU1 > VCU2 VCU2 will retain all core functionality and principles of VCU1, whilst improving core areas that enable a more portable, flexible, automated and profitable device. VCU2 Usability best practice through automation Increased reliability through refrigeration system optimisation Designed to
Slide 18: Vitrafy's Cryopreservation Software (LifeChain)
Vitrafy’s Cryopreservation Software (LifeChain) Following collaboration partner endorsement, Vitrafy is investing in rapidly expanding its software platform (LifeChain) to support scalability and enhanced functionality. Progress Update • LifeChain sample quality management software is focused on ret
Slide 19: Scaling Operational Capability
3 Scaling Operational Capability 19
Slide 20: Market Expansion
Market Expansion With a number of expected short term milestones, Vitrafy has brought forward and is accelerating the build out of our operational capability in the United States to align with the company’s market entry and growth strategies. • In December 2024, Vitrafy began its investment in build
Slide 21: Operational Update
Operational Update During the period, Vitrafy continued to deliver on operational milestones on its unwavering mission of becoming the global leader in cryopreservation and setting new industry quality standards for cryopreserved materials, preserving life. Progress Update • In the first half of FY2
Slide 22: Financial Summary
4 Financial Summary 22
Slide 23: Financial Summary – Income Statement
Financial Summary – Income Statement 31 31 Commentary December December % Change 2024 2023 YoY • Revenue generated within period relates to the thawing process 1H FY2025 Income Statement $ $ component of the Huon Aquaculture contract. This was based upon Revenue the base pack level, which is expecte
Slide 24: Financial Summary – Balance Sheet
Financial Summary – Balance Sheet As at 31 Commentary As at 30 June Balance Sheet December 2024 • Company with a cash balance of ~$14.4m at the end of period, and an 2024 Assets aggregate liquidity position of approximately ~$34.4m inclusive of $20.0m Current assets term deposits Cash and cash equiv
Slide 25: Financial Summary – Statement of Cash Flows
Financial Summary – Statement of Cash Flows 31 December 31 December % Change Commentary Statement of Cash Flows 2024 $ 2023 $ YoY • Receipts from customers represent the minimum volume for the Huon Cash flows from operating activities contract for a full season Receipts from customers 41,163 34,924
Slide 26: Outlook
5 Outlook 26
Slide 27: Outlook
Outlook With a number of expected short term milestones ahead, Vitrafy remains focused and clear on deliverables towards executing on its mission to become the global leader in cryopreservation, preserving life. H2 FY25 Establishing US presence and personnel Progressing the pipeline of business deve
Slide 28: Thank you
Thank you Contacts Mrs. Kathryn (Kate) Munnings Mr. Brent Owens Chief Executive Officer & Deputy Chief Executive Officer, Managing Director Co-Founder & Executive Director Phone: +61 419 661 117 Phone: +61 429 890 118 Email: kmunnings@vitrafy.com Email: bowens@vitrafy.com Simon Martin Michael Sapoun
Slide 29: Introduction to Cryopreservation
A1 Introduction to Cryopreservation 29
Slide 30: What is Cryopreservation?
What is Cryopreservation? Cryopreservation preserves biological materials by cooling samples to very low temperatures for future use. Quality cryopreservation improves availability, quality and consistency for life-saving therapeutic treatments. Standard Cryopreservation Supply Chain Common Commerci
Slide 31: Existing Supply Chain Management is Sub-standard
Existing Supply Chain Management is Sub-standard Vitrafy has a clear and focused mission to become the global leader in cryopreservation by significantly improving the cell survival of cryopreserved biological materials when compared to existing industry standards. ( J U L Y 2 0 2 4 – T H E I N D E
Slide 32: Board and Management
A2 Board and Management 32
Slide 33: Board and Senior Management
Board and Senior Management The Board and Senior Management bring relevant experience, including sector and business knowledge, financial management and corporate governance experience. Sonia Petering Kate Munnings Brent Owens Independent Chair & Chief Executive Officer & Deputy Chief Executive Offi
Slide 34: Market Opportunity
A3 Market Opportunity 34
Slide 35: Large Addressable Markets
Large Addressable Markets Vitrafy’s total addressable market is anticipated to grow at a CAGR of 10.6% to reach US$185 billion by 2030 underpinned by favorable tailwinds. 2030 TOTAL ADDRESSABLE MARKET1 MARKET DRIVERS Animal Breeding & Aquaculture Change in environmental standards Responsible far
Slide 36: Strategy and Competitive Advantage
Strategy and Competitive Advantage Vitrafy is focusing on three priority application areas where our Cryopreservation Technology will yield the greatest benefit. PRIORITY AQUACULTURE & HUMAN CELL & BLOOD PLATELETS APPLICATION AREA BOVINE REPRODUCTION GENE THERAPY Regulatory Unregulated Market Regula
Slide 37: Target Customers and Commercial Opportunity
Target Customers and Commercial Opportunity The three priority application areas Vitrafy is immediately focusing on represent significant commercial opportunities where Vitrafy has a clear competitive advantage PRIORITY AQUACULTURE & HUMAN CELL & BLOOD PLATELETS APPLICATION AREA BOVINE REPRODUCTION
Vitrafy Life Sciences — H1 FY2025 Earnings Presentation on 6ix